49 articles - From Friday Sep 01 2023 to Friday Sep 08 2023
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| Endosc Int Open |
|---|
Early versus late endoscopic treatment of pancreatic necrotic collections: A systematic review and meta-analysis. Early endoscopic treatment of PNC can be considered for indications such as infected necrosis or sterile necrosis with symptoms or complications; however, future large multicenter studies are required to further evaluate its safety. |
| Endoscopy |
Treatment of walled-off necrosis using lumen-apposing metal stent versus plastic stents: A systematic review and meta-analysis of data from randomized trials. Except for procedural duration, there is no significant difference in clinical outcomes in patients with WON treated using LAMS or plastic stents. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea. FMT performed twice at an interval of four weeks did not significantly reduce IBS-SSS score. However, more patients had improvement in abdominal bloating, which was associated with a reduction in hydrogen sulphide-producing bacteria. (ClinicalTrials.gov NCT03125564). |
| Am J Gastroenterol |
| Clin Gastroenterol Hepatol |
Comparative effectiveness of biologic therapies in preventing penetrating complications in patients with Crohn's disease. Anti-TNF therapy was associated with a lower risk of LPD and PPD compared with VDZ, and lower risk of LPD compared with UST. Further studies are needed to validate these findings and to determine potential reasons for these differences. |
Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-Based Study. This study is the first to draw a portrait of the distribution of IBD in urban China. The difference in IBD incidence between urban China and other countries suggests an association between the IBD burden and industrialization process. The accelerating urbanization and industrialization process in China, a country with a population of 1.4 billion people, will likely increase the burden of IBD. |
Real-world efficacy of dupilumab in severe, treatment-refractory, and fibrostenotic patients with eosinophilic esophagitis. In this population of severe, refractory, and fibrostenotic EoE patients, most achieved histologic, endoscopic, and symptom improvement with a median of 6 months of dupilumab, and esophageal stricture diameter improved. Dupilumab has real world efficacy for a severe EoE population, most of whom would not have qualified for prior clinical trials. |
| Endosc Int Open |
Comparison of guidewires for successful cannulation of biliary stenosis and targeting of biliary branches in ERCP. The results of this model test, which focused on the time required to complete the course around the model, can serve as a foundation for guidewire selection. This method holds potential utility in future guidewire development. |
Perforation-free removal of gastric gastrointestinal stromal tumors: Endoscopic inversion and strangulation of muscle layer and resection (EISMR). The median procedure time was 93 min (range, 58-120 min), and there were no major complications. We concluded that EISMR would be a safe and effective technique for endoscopic resection of gastric GISTs and may be an alternative to surgery or endoscopic submucosal dissection. |
| Gastroenterology |
A Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients with Low-Grade Dysplasia. The TSP-9 test outperformed the pathologists in risk-stratifying BE patients with LGD. Care guided by the test can provide an effective solution to variable pathology review of LGD, improving health outcomes by upstaging care to therapeutic intervention for patients at high risk for progression, while reducing unnecessary interventions in low-risk patients. |
Automated Artificial Intelligence Model Trained on a Large Dataset Can Detect Pancreas Cancer on Diagnostic CTs as well as Visually Occult Pre-invasive Cancer on Pre-diagnostic CTs. Automated AI model trained on a large and diverse dataset shows high accuracy and generalizable performance for detection of PDA on diagnostic CTs as well as for visually occult PDA on pre-diagnostic CTs. Prospective validation with blood-based biomarkers is warranted to assess the potential for early detection of sporadic PDA in high-risk subjects. |
Cell-in-Cell-Mediated Entosis Reveals A Progressive Mechanism in Pancreatic Cancer. Entosis is correlated with PDAC progression, especially in liver metastasis. NET1 is a newly validated entosis-related gene and a molecular marker of poor outcomes. PDAC cells generate a highly aggressive subpopulation marked by upregulated NET1 via entosis, which may drive PDAC progression. |
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Guselkumab intravenous induction was effective versus placebo in patients with moderately to severely active UC. Guselkumab was safe, and efficacy and safety were similar between guselkumab dose groups. |
Multistate model of the Natural History of Inflammatory Pancreatic Diseases: A Nationwide Population-based Cohort Study. Our findings reveal an increased risk of CP and pancreatic cancer in patients with a history of acute pancreatitis. However, most patients with CP and pancreatic cancer transitioned directly from a healthy state. |
| Gastrointest Endosc |
Endoscopic construction of an anti-reflux mucosal barrier for the treatment of gastroesophageal reflux disease, a pilot study. ARMV is a safe, feasible and effective procedure for GERD patients in this pilot study. Further prospective and comparative trials are needed to confirm its role among endoscopic anti-reflux therapies. |
The carbon cost of inappropriate endoscopy. The environmental impact of inappropriate endoscopic procedures in Italy and Europe is remarkable. These results highlight the need to adopt novel strategies aimed at reducing both the carbon footprint of digestive endoscopy and the rate of inappropriate procedures. |
| Gut |
Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial. A combination of endoluminal RFA and stenting was not superior to stenting alone in prolonging survival or improving stent patency in patients with malignant biliary obstruction. |
Predicting residual neoplasia after a non-curative gastric ESD: validation and modification of the eCura system in the Western setting: the W-eCura score. The eCura scoring system may be applied in Western countries to stratify the risk of LNM after a gastric HRR. A new score is proposed that may further decrease the number of unnecessary surgeries. |
| Hepatology |
LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia. These findings provide proof-of-concept evidence supporting LMO7 as a robust suppressor of NASH in the context of hyperlipidemia, indicating that targeting the LMO7-TRIM47 axis is a promising therapeutic strategy for NASH. |
Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry. The IAIHG-RR represents the world's largest AIH cohort with moderate-to-good data quality and a relevant number of liver-related events. The registry is a suitable platform for patient selection in future studies. Lack of complete biochemical response to treatment, non-white ethnicity, cirrhosis and PSC-AIH were associated with liver-related death and liver transplantation. |
Pegylated interferon-a for chronic hepatitis B…not ready to be shelved yet! new insights on its role using single-cell transcriptomics. The current editorial reviews a recent study related to the in-vivo use of PegIFN-a using single-cell RNA sequencing (scRNA-seq) technology. PegIFN-a reverts the transcriptome profile of treated samples close to that of the healthy population, diminishing the pro-inflammatory genes and 'inflammatory scores' which will be important for the HBV-cure program. |
| J Hepatol |
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis. Arid3a promotes cholestatic liver injury via impairing Mertk-mediated efferocytosis of apoptotic cholangiocytes by macrophages during cholestasis. The Arid3a-Mertk axis is a novel promising therapeutic target for cholestatic liver diseases. Impact and implications Macrophages play an important role in the pathogenesis of cholestatic liver diseases. This study reveals that macrophages with Arid3a upregulation manifest a pro-inflammatory phenotype and promote cholestatic liver injury by impairing Mertk-mediated efferocytosis of apoptotic cholangiocytes during cholestasis. Although we now offer a new paradigm how efferocytosis is regulated in a myeloid cell autonomous manner, the regulatory effects of Arid3a on chronic liver diseases remain to be further elucidated. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Endosc Int Open |
|---|
| Gastroenterology |
Gastric Intestinal Metaplasia: Real Culprit or Innocent Bystander as a Precancerous Condition for Gastric Cancer? Endoscopic surveillance for GIM may therefore be necessary, especially when there is extensive corpus GIM. Recent advances in image-enhanced endoscopy with integrated artificial intelligence have facilitated the identification of GIM and neoplastic lesions, which will impact preventive strategies in the near future. |
| Gut |
Abnormal gastrointestinal motility is a major factor in explaining symptoms and a potential therapeutic target in patients with disorders of gut-brain interaction. For each section regarding GI motor dysfunction, the article describes the preferred methods and the documented motor dysfunctions in DGBI based on those methods. The predominantly non-invasive measurements of gut motility as well as therapeutic interventions directed to abnormalities of motility suggest that such measurements are to be considered in patients with DGBI not responding to first-line approaches to behavioural or empirical dietary or pharmacological treatment. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Clin Gastroenterol Hepatol |
|---|
| Endosc Int Open |
| Endoscopy |
| Gastroenterology |
| Gut |
| Hepatology |
Letters to the editors and authors’ replies
| Clin Gastroenterol Hepatol |
|---|
| Gastroenterology |